InMode Receives Acquisition Proposal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: PRnewswire
- Acquisition Proposal Overview: On June 17, 2026, InMode Ltd. received an acquisition proposal from M.N. Business Strategy, offering $16.20 per share in cash for all outstanding ordinary shares not already owned, indicating strong market recognition of the company's value.
- Board Response: The company's Board has approved the formation of a special committee comprised solely of independent directors to evaluate the proposal, ensuring that the best interests of the company and all shareholders are maintained, demonstrating the company's seriousness regarding the proposal.
- Evaluation Process Uncertainty: While the special committee will consult with advisors for the evaluation, there is no assurance that this will lead to a transaction or any other strategic outcome, reflecting the company's cautious approach in the face of potential acquisition.
- Future Outlook: As a leading global provider of innovative medical technologies, InMode is committed to developing and marketing emerging RF technologies, and a potential acquisition could further enhance its market position and technological capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INMD
Wall Street analysts forecast INMD stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 14.540
Low
15.00
Averages
17.33
High
21.00
Current: 14.540
Low
15.00
Averages
17.33
High
21.00
About INMD
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into InMode Ltd. for Possible Securities Law Violations
- Governance Failures Exposed: Steel Partners Holdings L.P. publicly criticized InMode for a series of governance failures over the past six months, raising concerns that the CEO could acquire the company at a price lower than previously rejected by the board, which has alarmed investors.
- Insider Trading Allegations: The letter claims that InMode's CEO accumulated approximately 800,000 shares in open-market purchases between February 24 and March 10, 2026, during a narrow window surrounding significant corporate events, suggesting potential insider trading based on material non-public information.
- Stock Price Impact: Following the March 13, 2026 buyback announcement, InMode's stock price surged nearly 6%, indicating the market's sensitivity to governance issues and management behavior, which could affect investor confidence and the company's future market performance.
- Legal Consultation Opportunity: The Law Offices of Howard G. Smith are offering legal consultations for InMode investors, encouraging affected investors to reach out for potential claims to recover losses, highlighting the possible implications for corporate governance and shareholder rights.
See More
Steel Partners Raises Concerns Over InMode CEO-Led Buyout Proposal
- Acquisition Proposal Opposition: Steel Partners has expressed serious concerns regarding the CEO-led buyout proposal at $16.20 per share, arguing that this price is below the previously rejected $18 offer, which could harm shareholder interests.
- Governance Failure Allegations: Warren G. Lichtenstein, Executive Chairman of Steel Partners, highlighted in a letter that InMode has faced a series of governance failures over the past six months, allowing the CEO to potentially acquire the company at an unfair price, jeopardizing shareholder value.
- Independent Committee Demand: Steel Partners is urging InMode's board to retain a “truly independent” investment bank and form a “genuinely independent” special committee to ensure the acquisition process is free from CEO Moshe Mizrahy's interference, thereby protecting shareholder interests.
- Shareholder Dissent: Following Steel Partners' letter, fellow shareholder DOMA Perpetual Capital Management also announced its opposition to the buyout proposal, indicating widespread dissatisfaction with InMode's governance and acquisition process.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
InMode Stock Surges Following Acquisition Proposal
- Acquisition Proposal Surge: InMode disclosed an unsolicited buyout proposal from MN Business Strategy, led by CEO Moshe Mizrahy, offering $16.20 per share, representing a 21% premium over Tuesday's closing price, potentially attracting more investor interest.
- Stock Price Surge: Following the acquisition news, InMode's shares surged 11% in early Wednesday trading, hitting its 200-day moving average for the first time since May 4, indicating a positive market reaction to the proposal.
- Transaction Value Analysis: According to Koyfin data, InMode has approximately 63.26 million shares outstanding, implying a total transaction value of about $1.03 billion based on the proposed offer price, highlighting the potential impact of this acquisition proposal.
- Shift in Retail Sentiment: Retail sentiment on Stocktwits shifted from 'neutral' to 'bullish' a day prior to the acquisition announcement, reflecting investor optimism about the company's future prospects, despite the stock only rising about 9% over the past year.
See More
InMode Confirms Unsolicited Takeover Offer, Shares Rise 11%
- Takeover Offer Confirmation: InMode, an Israeli MedTech company, confirmed an unsolicited takeover offer from M.N. Business Strategy, a group backed by CEO Moshe Mizrahy, indicating strong interest in the company's future prospects.
- Offer Price Set: The proposal suggests an acquisition price of $16.20 per share, with InMode's board approving a special committee of independent directors to evaluate the bid, highlighting the company's seriousness regarding the potential transaction.
- Positive Stock Reaction: Following the announcement, InMode shares rose approximately 11% in premarket trading, reflecting the market's positive sentiment towards the acquisition proposal and potentially boosting investor confidence in the company's future.
- Transaction Uncertainty: Despite the board's evaluation of the offer, InMode stated that it does not guarantee a final transaction or any other strategic outcome, demonstrating a cautious approach to the acquisition process.
See More
InMode Receives Acquisition Proposal
- Acquisition Proposal Overview: On June 17, 2026, InMode Ltd. received an acquisition proposal from M.N. Business Strategy, offering $16.20 per share in cash for all outstanding ordinary shares not already owned, indicating strong market recognition of the company's value.
- Board Response: The company's Board has approved the formation of a special committee comprised solely of independent directors to evaluate the proposal, ensuring that the best interests of the company and all shareholders are maintained, demonstrating the company's seriousness regarding the proposal.
- Evaluation Process Uncertainty: While the special committee will consult with advisors for the evaluation, there is no assurance that this will lead to a transaction or any other strategic outcome, reflecting the company's cautious approach in the face of potential acquisition.
- Future Outlook: As a leading global provider of innovative medical technologies, InMode is committed to developing and marketing emerging RF technologies, and a potential acquisition could further enhance its market position and technological capabilities.
See More
Investigation into InMode Ltd. for Possible Securities Law Violations
- Governance Failures Exposed: Steel Partners Holdings L.P. publicly criticized InMode for a series of governance failures over the past six months, raising concerns that the CEO could acquire the company at a price lower than previously rejected by the board, which has alarmed investors.
- Insider Trading Allegations: The letter claims that InMode's CEO accumulated approximately 800,000 shares in open-market purchases between February 24 and March 10, 2026, during a narrow window surrounding significant corporate events, suggesting potential insider trading based on material non-public information.
- Stock Price Impact: Following the March 13, 2026 buyback announcement, InMode's stock price surged nearly 6%, indicating the market's sensitivity to governance issues and management behavior, which could affect investor confidence and the company's future market performance.
- Legal Consultation Opportunity: The Law Offices of Howard G. Smith are offering legal consultations for InMode investors, encouraging affected investors to reach out for potential claims to recover losses, highlighting the possible implications for corporate governance and shareholder rights.
See More
Steel Partners Raises Concerns Over InMode CEO-Led Buyout Proposal
- Acquisition Proposal Opposition: Steel Partners has expressed serious concerns regarding the CEO-led buyout proposal at $16.20 per share, arguing that this price is below the previously rejected $18 offer, which could harm shareholder interests.
- Governance Failure Allegations: Warren G. Lichtenstein, Executive Chairman of Steel Partners, highlighted in a letter that InMode has faced a series of governance failures over the past six months, allowing the CEO to potentially acquire the company at an unfair price, jeopardizing shareholder value.
- Independent Committee Demand: Steel Partners is urging InMode's board to retain a “truly independent” investment bank and form a “genuinely independent” special committee to ensure the acquisition process is free from CEO Moshe Mizrahy's interference, thereby protecting shareholder interests.
- Shareholder Dissent: Following Steel Partners' letter, fellow shareholder DOMA Perpetual Capital Management also announced its opposition to the buyout proposal, indicating widespread dissatisfaction with InMode's governance and acquisition process.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
InMode Stock Surges Following Acquisition Proposal
- Acquisition Proposal Surge: InMode disclosed an unsolicited buyout proposal from MN Business Strategy, led by CEO Moshe Mizrahy, offering $16.20 per share, representing a 21% premium over Tuesday's closing price, potentially attracting more investor interest.
- Stock Price Surge: Following the acquisition news, InMode's shares surged 11% in early Wednesday trading, hitting its 200-day moving average for the first time since May 4, indicating a positive market reaction to the proposal.
- Transaction Value Analysis: According to Koyfin data, InMode has approximately 63.26 million shares outstanding, implying a total transaction value of about $1.03 billion based on the proposed offer price, highlighting the potential impact of this acquisition proposal.
- Shift in Retail Sentiment: Retail sentiment on Stocktwits shifted from 'neutral' to 'bullish' a day prior to the acquisition announcement, reflecting investor optimism about the company's future prospects, despite the stock only rising about 9% over the past year.
See More
InMode Confirms Unsolicited Takeover Offer, Shares Rise 11%
- Takeover Offer Confirmation: InMode, an Israeli MedTech company, confirmed an unsolicited takeover offer from M.N. Business Strategy, a group backed by CEO Moshe Mizrahy, indicating strong interest in the company's future prospects.
- Offer Price Set: The proposal suggests an acquisition price of $16.20 per share, with InMode's board approving a special committee of independent directors to evaluate the bid, highlighting the company's seriousness regarding the potential transaction.
- Positive Stock Reaction: Following the announcement, InMode shares rose approximately 11% in premarket trading, reflecting the market's positive sentiment towards the acquisition proposal and potentially boosting investor confidence in the company's future.
- Transaction Uncertainty: Despite the board's evaluation of the offer, InMode stated that it does not guarantee a final transaction or any other strategic outcome, demonstrating a cautious approach to the acquisition process.
See More
InMode Receives Acquisition Proposal
- Acquisition Proposal Overview: On June 17, 2026, InMode Ltd. received an acquisition proposal from M.N. Business Strategy, offering $16.20 per share in cash for all outstanding ordinary shares not already owned, indicating strong market recognition of the company's value.
- Board Response: The company's Board has approved the formation of a special committee comprised solely of independent directors to evaluate the proposal, ensuring that the best interests of the company and all shareholders are maintained, demonstrating the company's seriousness regarding the proposal.
- Evaluation Process Uncertainty: While the special committee will consult with advisors for the evaluation, there is no assurance that this will lead to a transaction or any other strategic outcome, reflecting the company's cautious approach in the face of potential acquisition.
- Future Outlook: As a leading global provider of innovative medical technologies, InMode is committed to developing and marketing emerging RF technologies, and a potential acquisition could further enhance its market position and technological capabilities.
See More
